Neuronetics, Inc. (STIM)

Market Cap	247.46M
Revenue (ttm)	74.89M
Net Income (ttm)	-43.71M
Shares Out	65.81M
EPS (ttm)	-1.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	300,267
Open	3.660
Previous Close	3.770
Day's Range	3.660 - 3.800
52-Week Range	0.520 - 5.920
Beta	1.98
Analysts	Buy
Price Target	6.00 (+59.15%)
Earnings Date	May 6, 2025

About STIM

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company s...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 28, 2018
• Employees: 716
• Stock Exchange: NASDAQ
• Ticker Symbol: STIM
• Website: https://neurostar.com

Financial Performance

In 2024, Neuronetics's revenue was $74.89 million, an increase of 4.96% compared to the previous year's $71.35 million. Losses were -$43.71 million, 44.8% more than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for STIM stock is "Buy." The 12-month stock price forecast is $6.0, which is an increase of 59.15% from the latest price.

Price Target

$6.0

(59.15% upside)

Analyst Consensus: Buy